Hemin Market Report 2023 (Global Edition)

Global Hemin Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Hemin Industry growth. Hemin market has been segmented with the help of its Type, Application , and others. Hemin market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Report scope is customizable as we have a huge database of Hemin industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Type segment analysis of Global Hemin market.

350mg

The 350mg type segment  Revenue (USD Million) will be USD 478.66 Million by2028.

Panhematin or Hemin is lyophilised powder and given in the form of injection in the market. Panhematin is a hemin for injection used for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Panhematin is sterile, lyophilized black powder in a single dose dispensing vials. The vial contains equivalent of 350mg Hemin with 240 mg of sodium carbonate ans 325 mg of sorbitol mixed with sterile water for Injection.

313mg

Panhematin is a hemin for injection used for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Panhematin is sterile, lyophilized black powder in a single dose dispensing vials. The Panhematin vial contains 313 mg of Hemin, 215mg sodium carbonate, 300mg of sorbitol used for providing treatment for rare disease disorder, used for management of porphyrias. The pH may have been adjusted with hydrochloric acid; the product contains no preservatives. When mixed as directed with Sterile Water for Injection, USP, each 43 mL provides the equivalent of approximately 301 mg hematin (7 mg/mL).

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Hemin Industry. Request a Free Sample PDF!

Application segment analysis of Global Hemin market.

Hospital

The Hospital segment Revenue (USD Million) in Hemin will be USD 350.49 Million by 2028

Panhematin is a sterile, lyophilized powder suitable for intravenous administration and it is stored in dispensing vial that contains 350mg and 313 mg of Hemin and it also contains sodium carbonate, sorbitol in different proportions. The pH is adjusted with hydrochloric acid, mixing it with sterile water for Injection. The Hemin or Panhematin used by physicians that have experience in the management of porphyrias and rare disease disorder treatment. The Panhematin or Hemin is supplied directly to the hospital for treatment, where that standard, approved clinical and laboratory diagnostic and monitoring techniques are available for effective treatment for patients. Panhematin (hemin for injection) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.

Pharmacy

Panhematin is a sterile, lyophilized powder suitable for intravenous administration and it is stored in dispensing vial that contains 350mg and 313 mg of Hemin and it also contains sodium carbonate, sorbitol in different proportions. The pH is adjusted with hydrochloric acid, mixing it with sterile water for Injection. This medication is used to treat symptoms that occur with certain blood disorders such as porphyrias, rare blood disorder treatment. The hemin or Panhematin is provided to the pharmacy stores for treatment of patients suffering from rare blood disorders.

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Hemin market report 2023 Edition by contacting our team.

Hemin Market Regional Analysis

Region and country analysis section of Hemin Industry Analysis has been segmented into 5 major region such as North America, Europe, Asia Pacific, Middle East & Africa ,and Latin America (along with respective major contributing countries) and provides the revenue share, current trends.

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of Hemin market.

Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

Company Profile:

Recordati Rare Disease

Recordati Rare disease is part of Recordati group. The company has specialized in the production of orphan drugs, Hemin products, the company has innovative, quality products in the portfolio that boost its growth and value in the market. Company has advanced manufacturing plant with GMP. GDP certification, as they are committed to provide quality, safe service to patients. Recordati is a pharmaceutical company that provides treatment for patients with rare diseases. Recordati Rare disease Inc markets its specialty products in the Europe, the Middle East, the U.S.A., Canada, Russia, Japan and Australia, in some Latin American. The company has focused on unique production, packaging and quality distribution system with helps of dedicated team Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Company has team of expert that works with physician, to design customized programme and develop unique range of products and services in the market. The company has higher value in the market due to its clinical trials, various programme conducted to design unique products and services for customers in the market. The products included in portfolio are focused towards treatment of rare cancers, Cushing syndrome, nephropathic cystinosis, patent ductus arteriosus, Wilson disease, cystic fibrosis, phenylketonuria. The products comprise unique range of medications targeting various therapies designed to meet patient's conditions. It includes Carbaglu, Cystadane, Cosmegen for injection, Cystadrops, Cystagon, Isturisa, Juxtapid, Ledaga, Normosang, Panhematin Hemin Injection, Pedea, Signifor, Vedrop, Wilzin. The other products include NeoProfen injection, Peganone tablets, Ibulief injection.

RECENT NEWS

June 2020

Recordati Rare Disease Introduced First European Launch of Isturisa (Osilodrostat)

Recordati Rare Disease company has introduced Isturisa for treatment of Cushing Syndrome and commercially available in market of France, Europe.

MP Biomedical

MP Biomedicals has specialized in production of advanced lie science products, diagnostic products with optimized manufacturing facility developing more than 55000 products. The company has strong distribution network with presence across various countries including Europe, Asia, Australia, America. The company portfolio includes ISO certified quality products such as Life Science that includes biochemicals that has Hemin chloride from porcine, chemicals, antibodies, general lab equipment used in sample preparation, cancer research, plant research, cell biology, antibodies, electrophoresis, molecular biology. Diagnostic equipment that has biogenic amines, cardiac makers, contract manufacturing. Fine chemicals include IVD Manufacturing, sourcing services, organic synthesis, custom adsorbents, Empowered Products. Dosimetry solutions ensures safety and compliances with reliable and convenient radiation monitoring services. Dosimetry Products leak analysis kit, Badge boards. The applications involve environmental research, animal research, veterinary science research, cancer research, plant research, stem cell research.  MP Biomedical focused on reducing day-to-day complexities and they develop easy to use instruments and reagents delivering high-quality samples, high-quality, they have focused on optimization of small and large-scale manufacturing facilities. The have robust distribution network that provides quality, efficacy to ensure customer satisfaction.

RECENT NEWS

July 2020

MP Biomedicals Collaborated with A Star Developed Rapid Antibody Test Kit For COVID-19

MP Biomedicals has engaged in collaboration with A Star company for development of rapid antibody test kit for COVID-19 and this acquisition strengthen their operations building strong footprint in the market.

Top Companies Market Share in Hemin Industry: (In no particular order of Rank)

• Recordati Rare Diseases Inc.
• Abbott Laboratories
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..